dalteparin has been researched along with Graves Disease in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Graves Disease: A common form of hyperthyroidism with a diffuse hyperplastic GOITER. It is an autoimmune disorder that produces antibodies against the THYROID STIMULATING HORMONE RECEPTOR. These autoantibodies activate the TSH receptor, thereby stimulating the THYROID GLAND and hypersecretion of THYROID HORMONES. These autoantibodies can also affect the eyes (GRAVES OPHTHALMOPATHY) and the skin (Graves dermopathy).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rehman, A | 1 |
| Husnain, MG | 1 |
| Mushtaq, K | 1 |
| Eledrisi, MS | 1 |
1 other study available for dalteparin and Graves Disease
| Article | Year |
|---|---|
Cerebral venous sinus thrombosis precipitated by Graves' disease.
Topics: Adrenergic beta-Antagonists; Adult; Anticoagulants; Antithyroid Agents; Carbimazole; Computed Tomogr | 2018 |